Dulaglutide: A Literature Course on What the Studies Report

Dulaglutide has been studied as a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist in large randomised trials in type 2 diabetes, including head-to-head comparisons with semaglutide (PMID 29397376) and with the dual GIP/GLP-1 receptor agonist tirzepatide (PMID 35914543). This page is a structured reading course: it describes what the published record contains, module by module, and where each module stops. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a medicine or a medical condition. Nothing here is a protocol, a recommendation or a prediction of outcome.

Module 1: What Dulaglutide Is and How It Has Been Studied

Definition and class

In the clinical literature, dulaglutide is described as a weekly GLP-1 receptor agonist given by subcutaneous injection, and it is grouped with semaglutide as one of the "weekly glucagon-like peptide-1 receptor agonists" in randomised comparisons (PMID 37646192). It is a peptide-based biologic rather than a small synthetic research peptide: the GLP-1 analogue sequence is engineered for extended action so that trials could use a once-weekly dosing interval (PMID 29397376). Because of that engineering, dulaglutide is handled in the literature as a licensed injectable drug studied in humans, not as an exploratory laboratory reagent.

Populations and forms studied

The largest body of evidence comes from type 2 diabetes. Researchers in the REWIND trial studied dulaglutide 1.5 mg once weekly against placebo in people with type 2 diabetes at varying cardiovascular risk (PMID 31189511). SUSTAIN 7 used two dulaglutide dose levels, 0.75 mg and 1.5 mg once weekly, compared with semaglutide 0.5 mg and 1.0 mg once weekly (PMID 29397376). SURPASS J-mono compared tirzepatide 5 mg, 10 mg and 15 mg with dulaglutide 0.75 mg once weekly in Japanese patients with type 2 diabetes (PMID 35914543), and the SURPASS-CVOT programme used dulaglutide 1.5 mg once weekly as the active comparator in participants with type 2 diabetes and atherosclerotic cardiovascular disease (PMID 37758044).

Outside diabetes endpoints, dulaglutide has appeared in a population-based cohort analysis of dementia risk (PMID 39186787), a post hoc analysis of neurodegeneration biomarkers within REWIND (PMID 41988866), a randomised smoking-cessation trial in which alcohol consumption was analysed (PMID 37991022), and preclinical work on hepatic steatosis (PMID 40663700) and cardiomyocyte injury (PMID 33817486).

Limits of the evidence in Module 1

The trial record is concentrated in adults with type 2 diabetes, and several of the head-to-head studies were conducted specifically in Japanese populations (PMID 35914543, PMID 37646192). The verified literature summarised here does not describe manufacturing standards, purity testing or non-clinical handling of dulaglutide sold outside licensed supply chains.

Module 2: Mechanism as Described in the Literature

Papers on dulaglutide describe it as an agonist at the GLP-1 receptor, and comparative trials are framed around that shared class mechanism when dulaglutide is set against semaglutide (PMID 37646192) or against a molecule that adds GIP receptor activity (PMID 35914543). A pharmacodynamic substudy of SURPASS J-mono measured changes in pharmacodynamic variables after once-weekly dulaglutide 0.75 mg and after tirzepatide in Japanese patients with type 2 diabetes, which is the closest the verified set comes to a direct human mechanistic comparison (PMID 36184780).

Mechanistic work beyond glucose control

• Liver fat. In an obesity model, researchers reported that dulaglutide attenuated hepatic steatosis through a weight-independent mechanism, meaning the reduction in liver fat was not explained by weight loss alone (PMID 40663700).
• Cardiomyocytes. A cell-based study reported that dulaglutide alleviated lipopolysaccharide-induced injury in cardiomyocytes (PMID 33817486).
• Central effects. A randomised smoking-cessation trial analysed alcohol consumption during treatment and reported lower alcohol intake in the dulaglutide group than in the placebo group (PMID 37991022), an observation the authors framed as a signal for GLP-1 receptor involvement in reward-related behaviour rather than an established indication.
• Neurodegeneration markers. A post hoc analysis of the REWIND trial examined neurodegeneration biomarkers in participants who had received dulaglutide or placebo (PMID 41988866).

Limits of the evidence in Module 2

Mechanistic claims from cell and animal work do not transfer automatically to humans: the cardiomyocyte finding was generated in vitro (PMID 33817486) and the steatosis finding in an obesity model (PMID 40663700). The human pharmacodynamic data in this set come from one substudy in one country (PMID 36184780), and post hoc biomarker analyses are exploratory by design (PMID 41988866).

Module 3: Reported Outcomes by Study

The table below lists what each verified study set out to measure and what was reported. It is a map of the evidence, not a summary of expected results for any individual.

Limits of the evidence in Module 3

Two of the largest comparisons were designed to test other molecules, with dulaglutide serving as the active comparator (PMID 37758044, PMID 41406444), so their statistical questions were about non-inferiority or superiority of the comparator rather than about dulaglutide in isolation. Open-label designs, as used in SUSTAIN 7 (PMID 29397376) and COMING (PMID 37646192), leave room for expectation effects on subjective endpoints. Observational cohort results describe associations, not causation (PMID 39186787).

Module 4: Dulaglutide Side Effects: What Studies Report

Across the randomised literature, gastrointestinal complaints were the adverse events most frequently reported with dulaglutide. In SUSTAIN 7, researchers reported that gastrointestinal events such as nausea, vomiting and diarrhoea were the most common adverse events in both the dulaglutide and semaglutide arms (PMID 29397376). SURPASS J-mono similarly reported mild-to-moderate gastrointestinal adverse events as the most frequent findings in participants receiving dulaglutide 0.75 mg once weekly or tirzepatide (PMID 35914543), and the COMING study reported safety outcomes alongside efficacy for weekly dulaglutide and semaglutide in Japanese patients (PMID 37646192).

In the placebo-controlled setting, REWIND reported that gastrointestinal adverse events occurred more often with dulaglutide 1.5 mg once weekly than with placebo, and that such events contributed to treatment discontinuation in the dulaglutide group (PMID 31189511). The active-comparator cardiovascular outcome trial also collected safety data over long-term follow-up with dulaglutide 1.5 mg once weekly as the reference arm (PMID 41406444).

How adverse events were framed

• Gastrointestinal events were described as predominantly mild to moderate in the tirzepatide-versus-dulaglutide comparison (PMID 35914543).
• Discontinuation attributable to gastrointestinal intolerance was tracked as a distinct endpoint in the placebo-controlled trial (PMID 31189511).
• Head-to-head trials reported adverse events by treatment arm, which allows comparison between agents but not between individual dose levels outside the doses actually studied (PMID 29397376).

Limits of the evidence in Module 4

Trial safety populations were selected: participants met entry criteria, were monitored, and were mostly adults with type 2 diabetes (PMID 31189511, PMID 37758044). Rare events may not appear even in trials with thousands of participants, and adverse events observed with a licensed product studied at defined weekly doses cannot be extrapolated to unapproved material, other routes or other doses.

Module 5: Pharmacokinetics and Pharmacodynamics Where Data Exist

The verified papers in this course are clinical and preclinical outcome studies rather than dedicated pharmacokinetic reports, so absorption, distribution and clearance parameters are not stated here. What the record does show is the dosing interval that trials found workable: every randomised study cited used once-weekly subcutaneous administration, including dulaglutide 0.75 mg and 1.5 mg in SUSTAIN 7 (PMID 29397376) and dulaglutide 1.5 mg in the long-term cardiovascular trials (PMID 31189511, PMID 41406444).

On the pharmacodynamic side, a substudy of SURPASS J-mono measured change in pharmacodynamic variables after once-weekly dulaglutide 0.75 mg compared with tirzepatide in Japanese patients with type 2 diabetes (PMID 36184780). Preclinical work adds a separate pharmacodynamic observation: liver fat reduction that the researchers reported to be independent of weight change (PMID 40663700).

Limits of the evidence in Module 5

No half-life, bioavailability or exposure–response value is reported on this page because the verified set does not contain a dedicated pharmacokinetic study. The single human pharmacodynamic substudy examined one dulaglutide dose in one population (PMID 36184780), and animal pharmacodynamics may not correspond to human physiology (PMID 40663700).

Module 6: Regulatory Status, Stated Factually

Dulaglutide is a prescription biologic marketed as Trulicity and authorised by the US Food and Drug Administration and the European Medicines Agency for use in type 2 diabetes; the randomised trials summarised above were conducted in that indication (PMID 31189511, PMID 35914543). A licensed product of this kind is supplied as a finished dosage form through pharmacies under prescription.

Several points of regulatory status are worth separating clearly:

1. Approved product status. Dulaglutide has marketing authorisation as a finished drug product for a defined indication and defined weekly doses; the trial literature reflects those doses (PMID 29397376).
2. Research-use-only material. Peptides labelled "research use only" are not approved for human use and are not manufactured to pharmaceutical standards. That label carries no assurance of identity, purity or sterility, and none of the cited trials used such material.
3. Compounding. Under US law, compounders are generally not permitted to produce copies of commercially available approved drug products, and regulators have issued public communications about unapproved GLP-1 products, dosing errors with non-standard presentations, and salt forms that are not the approved active ingredient.
4. Off-label and investigational use. Studies examining dementia risk (PMID 39186787), neurodegeneration biomarkers (PMID 41988866) and alcohol consumption during smoking cessation (PMID 37991022) describe research questions, not approved uses.

Limits of the evidence in Module 6

Regulatory status changes over time and differs by jurisdiction; the summary above describes publicly documented status in general terms and is not legal advice. The cited papers do not address product labelling, importation or state-level rules.

What the Studies Did Not Test

The verified literature on dulaglutide leaves large areas unexamined:

• Healthy adults without metabolic disease. The randomised trials enrolled people with type 2 diabetes (PMID 31189511, PMID 37758044), so cosmetic or performance use in healthy people was not studied.
• Doses outside those tested. The comparisons cited used dulaglutide 0.75 mg or 1.5 mg once weekly (PMID 29397376, PMID 35914543); nothing in this set supports conclusions about other amounts or schedules.
• Combination with other peptides. No cited trial tested dulaglutide alongside other investigational peptides.
• Confirmatory neurological outcomes. Dementia and neurodegeneration signals came from observational data and post hoc analysis (PMID 39186787, PMID 41988866), not from trials designed to answer those questions.
• Human liver and cardiac endpoints for the mechanistic findings. The steatosis and cardiomyocyte results were generated in preclinical systems (PMID 40663700, PMID 33817486).
• Alcohol use disorder as a treated condition. The alcohol finding was an analysis within a smoking-cessation trial (PMID 37991022).

Read as a whole, the dulaglutide record is unusually mature for a peptide-based agent: multiple randomised trials, a long-term placebo-controlled cardiovascular outcome trial, and active-comparator studies against newer molecules. That maturity applies to the specific product, doses and populations that were studied, and not beyond them.

References

• Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial (Lancet, 2019)
• Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (New England Journal of Medicine, 2025)
• Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy) (Diabetes, Obesity & Metabolism, 2023)
• Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASS-CVOT design and baseline characteristics (American Heart Journal, 2024)
• Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial (The Lancet Diabetes & Endocrinology, 2018)
• Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial (The Lancet Diabetes & Endocrinology, 2022)
• Sodium-Glucose Cotransporter-2 Inhibitors, Dulaglutide, and Risk for Dementia: A Population-Based Cohort Study (Annals of Internal Medicine, 2024)
• Comparison of clinical efficacy and safety of weekly glucagon-like peptide-1 receptor agonists dulaglutide and semaglutide in Japanese patients with type 2 diabetes (COMING study) (Diabetes, Obesity & Metabolism, 2023)
• Dulaglutide and neurodegeneration biomarkers: REWIND post hoc analysis (Alzheimer's & Dementia, 2026)
• Dulaglutide Alleviates LPS-Induced Injury in Cardiomyocytes (ACS Omega, 2021)
• The GLP-1 Receptor Agonist Dulaglutide Attenuates Hepatic Steatosis in Obesity via a Weight-Independent Mechanism (Diabetes, 2025)
• Effects of dulaglutide on alcohol consumption during smoking cessation (JCI Insight, 2023)